New Possibilities for the Treatment of Crohn’s Disease
Aim. To review data on the efficiency and safety of using Ustekinumab in patients with Crohn’s disease.Key findings. Ustekinumab is a fully human monoclonal antibody of the IgG1k class to the p40 subunit of IL-12 and IL-23. The drug interrupts the cascade of humoral and cellular reactions leading to...
Saved in:
Main Authors: | Z. A. Mamieva, E. A. Poluektova, O. S. Shifrin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2019-12-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/416 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Features of Crohn's Disease Depending on the Age of Disease Onset
by: E. G. Ganich, et al.
Published: (2023-12-01) -
Difficulties the Conservative Treatment of Crohn’s Disease Complicated by Autoimmune Hemophilia A
by: E. L. Belyaeva, et al.
Published: (2020-01-01) -
Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy
by: A. I. Khavkin, et al.
Published: (2024-01-01) -
Significance of immune factors in Crohn's disease development
by: D. S. Stavtsev, et al.
Published: (2015-07-01) -
Efficacy of ileostomy in Crohn's disease of the large intestine with perianal involvement
by: Yu. A. Shelygin, et al.
Published: (2011-12-01)